Acorda Therapeutics Q3 EPS $(7.16) Up From $(11.00) YoY, Sales $27.71M Down From $33.51M YoY
Portfolio Pulse from bharat@benzinga.com
Acorda Therapeutics (NASDAQ:ACOR) reported a narrower Q3 loss of $(7.16) per share compared to $(11.00) per share in the same quarter last year. However, sales declined to $27.71M from $33.51M in the same period last year, representing a 17.30% decrease.
November 13, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Acorda Therapeutics reported improved Q3 EPS but lower sales compared to last year. EPS was $(7.16), up from $(11.00) YoY, while sales decreased by 17.30% to $27.71M from $33.51M YoY.
The mixed results with an improvement in EPS but a decline in sales could lead to a neutral short-term impact on ACOR's stock price. Investors may react positively to the reduced losses, but the decrease in sales could raise concerns about the company's growth prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100